NIFTY  9,430.80  0.75%
  SENSEX  30,592.00  0.96%
 CURRENCY  Rs  64.73/$ 72.75/€, 84.05/£
  GOLD  28,728.00  0.05%
  SILVER  39,852.00  0.05%
  DAX  12,642.90  -0.13%
  FTSE  7,514.90  0.40%
  CAC  5,341.34  -0.11%
  HANG SENG  25,428.50  0.10%
  NIKKEI  19,813.10  0.36%
  Shanghai Composite  3,107.83  0.71%
  DOW JONES  21,012.40  0.36%
  NASDAQ  6,163.02  0.40%
  S&P 500  2,404.39  0.25%
EARNINGS REPORT : Kalyani Steels Q4 PAT Rs 37.2 Cr Vs Rs 29 Cr, Up 28% YoY EARNINGS REPORT : Kalyani Steels Q4 Sales Rs 366 Cr Vs 304 Cr, Up 20.4% YoY EARNINGS REPORT : Redington Q4 PAT Rs 153 Vs 138 Cr, Up 11% YoY EARNINGS REPORT : Redington Q4 Total Income Rs 10,813 Cr Vs Rs 10,491 Cr, Up 3% YoY EARNINGS REPORT : West Coast Q4 PAT Rs 49 Cr Vs Rs 6.8 Cr YoY EARNINGS REPORT : West Coast Paper Q4 Sales Rs 473 Cr Vs Rs 455 Cr, Up 4% YoY

USFDA Hit For Ranbaxy

Video:

Play this video

September 16: The USFDA has issued an import alert against Ranbaxy and says that it will not be able to import drugs produced at its Mohali unit. While the order does not have a significant financial impact on the company, it has dampened sentiment as the unit was being primed for new launches. Bloomberg TV India discusses how this ban raises doubts about the launch of some of the company’s key exclusive drugs.